- Home
- BJDX vs TOVX Comparison
BJDX vs TOVX Comparison
Compare BJDX & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BJDX
- TOVX
- Stock Information
- Founded
- BJDX 2015
- TOVX 2001
- Country
- BJDX United States
- TOVX United States
- Employees
- BJDX N/A
- TOVX N/A
- Industry
- BJDX Medical Specialities
- TOVX Biotechnology: Pharmaceutical Preparations
- Sector
- BJDX Health Care
- TOVX Health Care
- Exchange
- BJDX Nasdaq
- TOVX Nasdaq
- Market Cap
- BJDX 3.9M
- TOVX 3.8M
- IPO Year
- BJDX 2021
- TOVX 2006
- Fundamental
- Price
- BJDX $1.70
- TOVX $0.28
- Analyst Decision
- BJDX
- TOVX Hold
- Analyst Count
- BJDX 0
- TOVX 1
- Target Price
- BJDX N/A
- TOVX N/A
- AVG Volume (30 Days)
- BJDX 103.5K
- TOVX 44.2M
- Earning Date
- BJDX 11-07-2025
- TOVX 11-11-2025
- Dividend Yield
- BJDX N/A
- TOVX N/A
- EPS Growth
- BJDX N/A
- TOVX N/A
- EPS
- BJDX N/A
- TOVX N/A
- Revenue
- BJDX N/A
- TOVX N/A
- Revenue This Year
- BJDX N/A
- TOVX N/A
- Revenue Next Year
- BJDX $55.56
- TOVX N/A
- P/E Ratio
- BJDX N/A
- TOVX N/A
- Revenue Growth
- BJDX N/A
- TOVX N/A
- 52 Week Low
- BJDX $1.26
- TOVX $0.26
- 52 Week High
- BJDX $10.20
- TOVX $2.08
- Technical
- Relative Strength Index (RSI)
- BJDX 41.64
- TOVX 41.23
- Support Level
- BJDX $1.39
- TOVX $0.26
- Resistance Level
- BJDX $2.34
- TOVX $0.29
- Average True Range (ATR)
- BJDX 0.17
- TOVX 0.06
- MACD
- BJDX -0.10
- TOVX -0.00
- Stochastic Oscillator
- BJDX 28.16
- TOVX 2.19
About BJDX Bluejay Diagnostics Inc.
Bluejay Diagnostics Inc is a medical diagnostics company focused on improving patient outcomes using its Symphony System, a cost-effective, rapid, near-patient testing system for sepsis triage and monitoring of disease progression. Bluejay's first product candidate, an IL-6 Test for sepsis, is designed to provide accurate, reliable results in approximately 20 minutes from 'sample-to-result' to help medical professionals make earlier and better triage/treatment decisions.
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.